NASDAQ:FOMX

Menlo Therapeutics (FOMX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.99
$2.99
50-Day Range
$2.99
$2.99
52-Week Range
$1.97
$4.84
Volume
N/A
Average Volume
518,350 shs
Market Capitalization
$184.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FOMX stock logo

About Menlo Therapeutics Stock (NASDAQ:FOMX)

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

FOMX Stock News Headlines

His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
Corcept Appoints Roberto Vieira as President, Oncology
Independent Living Communities Near Menlo Park, CA
Dr. Sun Hae Choi
See More Headlines
Receive FOMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2019
Today
4/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & Botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:FOMX
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Net Income
$-74,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$1.70 per share

Miscellaneous

Free Float
N/A
Market Cap
$184.12 million
Optionable
Optionable
Beta
1.66
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. David T. Domzalski (Age 52)
    CEO & Director
  • Mr. Ilan Hadar M.B.A. (Age 50)
    MBA, CFO & Country Mang.
  • Ms. Mutya Harsch (Age 44)
    Gen. Counsel & Chief Legal Officer
  • Dr. Darrell S. Rigel M.D. (Age 69)
    MS, Consultant
  • Dr. Iain A. Stuart (Age 46)
    Chief R&D Officer

FOMX Stock Analysis - Frequently Asked Questions

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc. (NASDAQ:FOMX) announced its quarterly earnings data on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07.

What other stocks do shareholders of Menlo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), OPKO Health (OPK) and Pfizer (PFE).

This page (NASDAQ:FOMX) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners